Hyponatremia is the most common electrolyte abnormality seen in hospitalized patients, and even in its mildest form, it is associated with increased morbidity and mortality. The burden of hyponatremia in the hospital setting is substantial and is expected to increase as the population ages. Being able to adequately treat patients requires hospitalists to clearly diagnose hyponatremia and its underlying etiology. Unfortunately, optimal treatment strategies are not well defined due to the marked differences in symptoms and clinical outcomes based on the chronicity and severity of hyponatremia. This archived symposium will provide hospitalists with the latest information on the clinical diversity of hyponatremia, provide strategies for accurate diagnosis of acute and chronic hyponatremia, provide current healthcare guidelines and optimal treatment strategies, and assist in the formulation of individualized treatment plans.
To provide hospitalists with up-to-date information and guidelines for the management and treatment of hospitalized patients with hyponatremia.
This activity has been designed to meet the educational needs of hospitalists and other general internal medicine providers at hospitals who are involved in the perioperative care of patients with hyponatremia. No prerequisites required.
At the conclusion of this activity, participants should be able to:
- EVALUATE the impact of uncorrected hyponatremia on outcome measures in the hospitalized patient.
- RECOGNIZE the clinical spectrum of hyponatremia in the hospital setting.
- DIAGNOSE hyponatremia according to etiology and pathophysiology.
- FORMULATE treatment plans for correcting hyponatremia based on disease- and patient-specific factors.
Full Disclosure Policy Affecting CME Activities:
The University of Virginia School of Medicine, as an ACCME accredited provider, endorses and strives to comply with the Accreditation Council for Continuing Medical Education (ACCME) Standards of Commercial Support, Commonwealth of Virginia statutes, University of Virginia policies and procedures, and associated federal and private regulations and guidelines on the need for disclosure and monitoring of proprietary and financial interests that may affect the scientific integrity and balance of content delivered in continuing medical education activities under our auspices.
The University of Virginia School of Medicine requires that all CME activities accredited through this institution be developed independently and be scientifically rigorous, balanced and objective in the presentation/discussion of its content, theories and practices.
All faculty presenters participating in an accredited CME activity are expected to disclose relevant financial relationships with commercial entities occurring within the past 12 months (such as grants or research support, employee, consultant, stock holder, member of speakers bureau, etc.). The University of Virginia School of Medicine will employ appropriate mechanisms to resolve potential conflicts of interest to maintain the standards of fair and balanced education to the participant. Questions about specific strategies can be directed to the Office of Continuing Medical Education, University of Virginia School of Medicine, Charlottesville, Virginia.
The faculty and staff of the University of Virginia Office of Continuing Medical Education have no financial affiliations to disclose.
The following relationships have been reported for faculty of this activity:
Mitchell H. Rosner, MD, FACP (Course Director)
Henry B. Mulholland Professor of Medicine
Chairman, Department of Medicine
University of Virginia Health System
Dr Rosner reports serving as a consultant for Johnson & Johnson, Novartis, and Otsuka America Pharmaceutical, Inc.
Bartho Caponi III, MD, FACP, FHM
Clinical Assistant Professor
Division of Hospital Medicine, Department of Medicine
University of Wisconsin School of Medicine and Public Health
Dr Caponi reports serving as a consultant for CME Enterprise, Inc.
Joseph Verbalis, MD
Professor of Medicine and Physiology
Chief of the Division of Endocrinology and Metabolism
Dr Verbalis reports serving as a consultant for Cornerstone Therapeutics Inc; serving as a consultant and on the advisory committee/board for Ferring Pharmaceuticals; and performing industry funded research/serving as an investigator, serving as a consultant, and serving on the speakers’ bureau/as a faculty member/peer reviewer, and serving on the advisory committee/board for Otsuka America Pharmaceutical, Inc.
Disclosure of Discussion of Non-FDA–Approved Uses for Pharmaceutical Products and/or Medical Devices
The University of Virginia School of Medicine, as an ACCME provider, requires that all faculty presenters identify and disclose any off-label uses for pharmaceutical and medical device products. The University of Virginia School of Medicine recommends that each physician fully review all the available data on new products or procedures prior to clinical use.
All faculty have indicated that they have not referenced unlabeled or unapproved uses of drugs or devices.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of the University of Virginia School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
Click on link below to listen to and follow along with the slides of this previously held live symposium.
Please note, webcast archive for reference only, no CE is offered for this activity.